Příspěvky

Zobrazují se příspěvky z srpen, 2011

Reducing Excessive Toxicity in Ovarian Cancer Treatment: Primary Chemotherapy

Obrázek
Reducing Excessive Toxicity in Ovarian Cancer Treatment: Primary Chemotherapy:


...here has been a lack of good evidence for the routine use of neuroprotective agents in the chemotherapy regimen, such as vitamin E, amifostine, amitriptyline, dimensa, gabapentin, glutamine and lamotrigine.[35] There are ongoing Phase II/III trials evaluating specific agents; however, at this time, the American Society of Clinical Oncology does not support their routine use.[34–36]

The treatment of neuropathic pain has several options, but again their use has not been validated by large, randomized controlled trials.
In small numbers of patients gabapentin 400 mg three-times daily and amitriptyline 10–50 mg have been shown to provide relief in severe neuropathic pain patients.[33,34]
Prednisone doses of 10 mg twice a day beginning 24 h after therapy for 5 days has demonstrated some improvement in chemotherapy-associated neuropathy.[33] A discussion with the patient on the lack of good data to support …

Paraneoplázie

Paraneoplastické syndromy

definice:příznaky, které nepravidelně doprovázejí některé nádory a u nichž není vždy jasná patofyziologická souvislost mezi nádorem a paraneoplastickým projevem.
Nejsou vyvolány mechanicky, ale nepřímo signálními látkami, které nádor uvolňuje , autoimunitními mechanismy a nepřesně popsanými pochody

Dělení

OBECNÉ PARANEOPLASTICKÉ PŘÍZNAKY

Subferilie , febrilie ( horečka nejasného původu)Anorexie a kachexieOrtostatická hypotenzeProjevy snížené imunitní obranyHEMATOLOGICKÉ erytropoézaanémie chronických chorobpolyglobulie ( nádory ledvin , plic)autoimunitní hemolytická anémiemikroangiopatická hemolytická anémieaplastická anémie (pure red cell aplasia)leukocytopoézaleukocytosaleukocytopeniemegakaryocytopoézatrombocytozatrombocytopeniekoagulacehyperkoagulacežilní tromboembolismusDICantifosfolipidový syndromimunitní inhibitory koagulace

ENDOKRINNÍ
SIADHParaneoplastický Cushingův syndromParaneoplastický hyperkalcemický syndromParaneoplastická hypoglykemieEktopocká produkce c…

Onkologie v číslech

Metastatic Non-Small-Cell Lung Cancer : Abstract and Introduction

Meta-Analysis Defines Congestive Heart Failure Risk With Sunitinib

Meta-Analysis Defines Congestive Heart Failure Risk With Sunitinib

....The relative risks of any CHF and high-grade CHF with sunitinib compared with placebo were statistically significant, at 1.81 and 3.30, respectively....


....Sunitinib also increases the risk of hypertension, in line with other VEGF inhibitors, such as sorafenib and bevacizumab. As hypertension is a well known risk factor for CHF, it's possible that sunitinib use increased CHF through this mechanism, the investigators note.
Summing up, Dr. Choueiri and colleagues say clinicians need to be aware of the risk of CHF with sunitinib treatment to provide early intervention and balance therapeutic benefit with this potentially life-threatening adverse effect....

Degarelix Superior to Leuprolide for Prostate Cancer

Degarelix Superior to Leuprolide for Prostate Cancer:

...In men with prostate cancer, long-term outcomes of androgen deprivation therapy are better with degarelix than with leuprolide, new trial data show.

The data are from a five-year extension of the 12-month phase III CS21 trial, in which degarelix (Firmagon) suppressed testosterone to castrate levels as effectively as -- but faster than - leuprolide (Lupron).....

After Prostate Surgery, Some Men Leak During Sex

After Prostate Surgery, Some Men Leak During Sex:

....Incontinence during sex is a long-lasting problem for roughly one in eight men who've had a prostatectomy, a study of more than 1,400 patients has found.

Although the urine leakage resolved for some men over time, 36% of them still had the problem -- called climacturia -- two years after surgery. And 12% called it a "major bother."...

Chemo Doublet as a Standard for Elderly NSCLC Patients

Chemo Doublet as a Standard for Elderly NSCLC Patients:

.... The doublet significantly improved overall survival (10.3 vs 6.2 months; P < .0001) and progression-free survival (6 vs 2.8 months; P < .0001), compared with the single agent.

However, the doublet also increased toxicity. Grade 3/4 neutropenia, febrile neutropenia, thrombocytopenia, anemia, and sensory neuropathy were significantly more frequent than with a single agent.....

Estrogen Receptor Antagonist Reduces Death Risk in ER-Positive Breast Cancer Patients

Estrogen Receptor Antagonist Reduces Death Risk in ER-Positive Breast Cancer Patients: dying

. In women with ER-positive disease, tamoxifen reduces the risk of dying from breast cancer by about a third over 15 years — during the 5 years it is taken and for 10 years after it is stopped, according to a meta-analysis published online July 29 in the Lancet. ... The relative risk (RR) for recurrence was nearly halved during tamoxifen treatment (0.53 during years 0 to 4). It was also significantly reduced, by about a third (RR, 0.68), during years 5 to 9, but then it plateaued (RR, 0.97) during years 10 to 14, suggesting that there was no further gain or loss after year 10, the researchers explain.... .....
Tamoxifen reduces rates of recurrence and mortality from breast cancer when given to women with early breast cancer, independent of chemotherapy, nodal status, and tumor stage.Adverse effects of tamoxifen include uterine cancer, with an absolute risk increase of 2.6% for women older than 5…

TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009 | DocGuide

TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009 | DocGuide:

....Meta-analyses had shown that taxane-containing chemotherapy reduced the relative risk of relapse and death by 20-30%, apparently with moderate side effects

Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial | DocGuide

Obrázek

Exposure to bisphosphonates and risk of colorectal cancer: A population-based nested case-control study | DocGuide

Exposure to bisphosphonates and risk of colorectal cancer: A population-based nested case-control study | DocGuide:

..... The results from this study suggested that exposure to BPs, especially risedronic acid, may be associated with a decreased risk of developing CRC.

Acid reflux and oesophageal cancer | DocGuide

Acid reflux and oesophageal cancer | DocGuide:

Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas. One in 50 of the adult population develops Barrett's as a consequence of chronic gastro-oesophageal reflux.
...There are several ongoing clinical trials which are aiming to provide data using anti-inflammatory therapies to tackle this important premalignant condition. There is new data presented which suggests that data from the aspirin esomeprazole chemoprevention trial (AspECT) may hold the clue to disease treatment and that the cytokine TNF-α seems to be a key signalling molecule in the metaplasia-dysplasia-carcinoma sequence. Specifically it appears that both epigenetic and inherited genetics cooperate to modulate the prognosis....

Androgen Deprivation Therapy Doesn't Raise CV Risk

Sipuleucel-T Safe in Men With Metastatic Prostate Cancer

Sipuleucel-T Safe in Men With Metastatic Prostate Cancer:


Sipuleucel-T, the first therapeutic vaccine for prostate cancer, is safe for use in outpatients, according to a new report.

Designed to stimulate an immune response against prostate cancer, sipuleucel-T (Provenge) must be prepared specifically for each patient using autologous dendritic cells. It was approved by the U.S. Food and Drug Administration in April 2010 for men with asymptomatic or minimally symptomatic metastatic hormone-refractory prostate cancer

Some BRCA1 Carriers Less Sensitive to Taxane

Some BRCA1 Carriers Less Sensitive to Taxane:

Taxanes are less effective in some patients with BRCA1 mutations, according to Dutch investigators.

If confirmed, the results "can have a major impact on the choice of type of (adjuvant) chemotherapy in BRCA1 mutation carriers with hormone receptor negative or triple negative breast cancer," said lead author Dr. Mieke Kriege in email to Reuters Health.

In a July 14th online paper in Cancer, Dr. Kriege and colleagues at Erasmus MC-Daniel den Hoed Cancer Center in Rotterdam note there is growing evidence from preclinical studies that sensitivity to taxanes requires a functional BRCA1 protein.....

Vitamin D Improves Pain From Aromatase Inhibitors

No Screening for Bladder Cancer: Insufficient Evidence

No Screening for Bladder Cancer: Insufficient Evidence

...More than 90% of all cases of bladder cancer are classified as transitional-cell carcinomas, and most of these present as superficial tumors. "Some of these tumors may never progress to advanced disease," the task force points out.
However, many of these superficial tumors (50% to 70%) will recur after treatment, and about 10% to 20% progress to the invasive stage. At the time of diagnosis, about 25% of all cases of bladder cancers and 20% to 40% of all invasive tumors have already metastasized to the lymph nodes at the time of diagnosis. "Invasive bladder cancer is associated with a poor prognosis," the authors add, because "treatment has limited efficacy in these cases."---

Bladder Cancer Risk From Smoking Higher Than Expected

Bladder Cancer Risk From Smoking Higher Than Expected:

As compared with never-smokers, both former and current smokers had an increased risk for bladder cancer. Former smokers had a 2.2 times increased risk for bladder cancer, and current smokers had a risk that was approximately 4 times higher relative to never-smokers.

FDA Approves Zelboraf (Vemurafenib) for Metastatic Melanoma

FDA Approves Zelboraf (Vemurafenib) for Metastatic Melanoma

The drug is specifically indicated for patients with melanoma whose tumors have V600E mutations in theBRAF gene. An estimated 50% of patients with melanoma have this type of BRAF mutation, which does not occur in normal cells. The drug is not indicated for use in patients without the mutation.......

Erbitux má úhradu 1. linie léčby mCRC

Obrázek

Domácí péče Vysočina

Obrázek
zdroj: MZ ČRNárodní centrum domácí péče ČR 6301 Bystřice nad PernštejnemNázevAdresaČíslo telefonuHOME CARE - domácí zdravotní péčeHornická, 59301 Bystřice nad Pernštejnem605260637HOME CARE - domácí zdravotní péčePříční, 59301 Bystřice nad Pernštejnem566553310, 605261011 6302 Havlíčkův BrodNázevAdresaČíslo telefonuOblastní c

Topotekan

Obrázek
v přípravě


Topotecani hydrochloridum

ATC  kód  L01XX17
Charakteristika
Semisyntetický derivát kamptotecinu 
Kamptecin - alkaloid izolovaný z asijského stromu Camptotheca acuminata


Preparáty  zde
p.o. tob. bílé: 0,25 mg, růžové: 1 mgi.v. (balení á 1mg a á 4mg) počet ampulí v balení 1 nebo 5 (světle žlutý až zelenožlutý prášek rozpustný ve vodě)Cena 8/2011 inj. 1mg    2596,75 tbl.  1mg1451,59 Kč Mechanismus účinku Kamptotecin inhibuje topoizomerázu Iv S fázi buněčného cyklu, která je  ve zvýšené míře exprimována u většiny nádorových buněk.

Inhibice topoizomerázy I topotekanem vede v buňce k indukci jednovláknových zlomů DNA, a tím k buněčné smrti